Elpiscience (Suzhou) Biopharma, Ltd.

Privately held: no public share price · China

Assets

(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
2Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 2/3
OX40 (agonist)Monoclonal antibody
Non-Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
OrdastobartPhase 2Non-Small Cell Lung Cancer
Est. primary completion 2027-02-28 · NCT06623136 · CT.gov ↗
What to watch
2029 (1)
December 2029 (1)
OrdastobartPhase 2/3Head and Neck Squamous Cell Carcinoma (HNSCC), HPV Oropharyngeal Squamous Cell Carcinoma (HPV+ OPSCC)
Est. primary completion 2029-12 · NCT06295731 · CT.gov ↗
What to watch
2033 (1)
July 2033 (1)
OrdastobartPhase 1/2Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma …
Est. primary completion 2033-07 · NCT04198766 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

8 September 2026Topline resultINBRX-106Phase 2 portion of NCT06295731: INBRX-106 + pembrolizumab confirmed ORR 48.3% vs 26.5% (primary endpoint analysis)
Inhibrx Biosciences · Source ↗

Financial reports

No financial reports recorded.